CMPS · COMPASS Pathways Plc · Stock research

Reference close $13.33 (2026-08-21). 52-week high $15.07, so the tape sits 11.5% under it. RSI(14) 67.0. Three-month price change +12.9%.

CMPS — COMPASS Pathways plc

Current Thesis

The clinical binary closed on 2026-07-07 with positive 26-week COMP006 Phase 3 data in treatment-resistant depression. What trades now is regulatory execution: a rolling NDA that management said on 2026-08-05 is on track for completion of all modules in Q4 2026, an H1 2027 US launch gated on both FDA approval and DEA rescheduling, and $433.3M of cash at 2026-06-30 the company says funds operations into 2028.

The change since the last update is that the 30-day window is no longer empty. FDA has scheduled a public hearing for 2026-09-14, 12:30–4:30pm ET, hybrid, on the therapeutic use of psychedelic drug products in supervised, supportive settings — announced in the Federal Register on 2026-07-14, with oral-testimony requests closing 2026-08-21 and written comments open to 2026-10-05 (Foley Hoag alert, 2026-08-18). The four listed topics — provider training and credentialing, patient safety, access, and data standardisation — are the exact architecture of a REMS and of the supervised-administration model COMP360 has to be sold into. The hearing decides nothing, but it is the first public read on how restrictive the access framework is likely to be, and it lands while the stock is roughly flat over two weeks ($13.54 on 2026-08-07 to $13.33 on 2026-08-21) with RSI still at 67.

Bullish and bearish views on COMPASS Pathways Plc

The model's bull view on COMPASS Pathways Plc (CMPS), in brief: Rolling NDA submission and initial FDA review both underway, with final submission on track for Q4 2026 and launch guided to H1 2027 (Q2/H1 2026 results release, 2026-08-05). The bear view: The mixed shelf prospectus filed 2026-08-05 remains on file with no priced deal through the latest news scan. Both cases follow in full.

Bull Case

• Rolling NDA submission and initial FDA review both underway, with final submission on track for Q4 2026 and launch guided to H1 2027 (Q2/H1 2026 results release, 2026-08-05). Reiterated by management at Canaccord Genuity's 46th Annual Growth Conference fireside chat on 2026-08-12.
• COMP360 was granted rolling NDA review and selected for the Commissioner's National Priority Voucher programme on 2026-04-24. FDA's stated target for CNPV reviews is one to two months; management characterised that as aspirational on 2026-08-12 and pointed to esketamine's 50-day approval as the precedent worth watching.
• Cash and cash equivalents $433.3M at 2026-06-30, which the company states funds operations and capex into 2028 — past the guided launch window (2026-08-05).
• On DEA timing, management described the traditional path as roughly 90 days post-FDA-approval, with Executive Order 14401 directing expedited controlled-substance scheduling review for FDA-approved psychedelics (2026-08-12 fireside; EO cited in Foley Hoag alert 2026-08-18). Separately, the company said on 2026-08-05 that about 90% of the US patient population lives in states intending to reschedule within 30 days of federal action.
• Commercial build continues into the filing: inducement grants dated 2026-08-05 covering options for 139,355 shares plus RSUs and nominal-cost options for 66,300 shares to fourteen newly hired employees, exercise price $11.25.
• 2026-08-06: VA collaboration on PIVOT, a five-site double-blind randomised trial of COMP360 in veterans with TRD, with or without PTSD; the company donates study drug and the government sponsor carries trial cost.
• Target band still sits above the tape: B. Riley $22 and Morgan Stanley $18 (both 2026-08-06), RBC $21 (2026-08-06), Evercore ISI Outperform at $21 from $8 in the readout cluster.

Bear Case

• The mixed shelf prospectus filed 2026-08-05 remains on file with no priced deal through the latest news scan. Capacity is not a raise, but the precedent is eight months old: a $150.0M ADS offering was priced on 2026-02-18.
• Q2 GAAP net loss $253.8M, $(1.88) per share, including a $205.6M non-cash change in the fair value of warrant liabilities. That liability is remeasured upward as the ADS price rises, so the GAAP headline deteriorates when the equity works.
• The 2026-09-14 hearing is a two-way event. Testimony emphasising provider credentialing burdens, monitoring requirements or narrow access criteria would put a cost-of-delivery and reimbursement problem in front of a launch that has none of its pricing publicly set.
• Sell-side dispersion is extreme and unresolved: Wells Fargo initiated Equal-Weight at $13 on 2026-07-27, level with the tape, while HC Wainwright's target sits at $65 after being cut from $70 on 2026-08-07. A cluster that wide means the marginal buyer has no anchor.
• Pre-revenue with commercial headcount already hired: H1 2026 R&D $55.7M and G&A $39.6M against 135,722,306 ordinary shares at 2026-06-30.
• Momentum has stalled without breaking. The three-month price change reads +12.9% at 2026-08-21 versus +36.6% at 2026-08-07 — mostly the comparison window rolling forward past the May base rather than a drawdown, since the price itself moved only from $13.54 to $13.33 across that stretch. Inference: the July impulse has stopped extending.

Setup & Price Structure

• The narrative is maturing. The fresh-headline phase ran 2026-07-07 (COMP006) through 2026-08-06 (VA collaboration, conference schedule) and has since gone quiet — the only tape item after that in the scan window is a 2026-08-12 unusual-options roundup. Coverage is broad and the readout is priced in, yet the regulatory leg still produces dated events (2026-09-14 hearing, Q4 NDA completion), which is why this is not late-cycle exhaustion.
• $13.33 on 2026-08-21, 11.5% below the $15.07 52-week high. The stock has held the post-readout shelf for two weeks without reclaiming the July highs.
• RSI(14) 67.0 while price is slightly below the 2026-08-07 close — an elevated oscillator that has not been confirmed by a new high.
• Crowding observables, stated as observables: sixteen analysts covering per aggregator counts, with published targets spanning $13 to $65; a mixed shelf live since 2026-08-05 with terms undisclosed; inducement options struck at $11.25 on 2026-08-05; no earnings date inside 30 days; a whale-alert/unusual-options screen naming the ticker on 2026-08-12. No insider open-market selling appears in the scan window.
• The $11.25 grant strike and the early-August consolidation zone mark the area the July leg would have to give back before the structure is in question.

Catalyst Calendar (next 30 days)

• 2026-09-14 — FDA public hearing, 12:30–4:30pm ET, hybrid, on therapeutic use of psychedelic drug products in supervised, supportive settings. Docket topics: provider training and credentialing, patient safety, access, data standardisation.
• 2026-10-05 — written-comment deadline for that docket (just outside the 30-day window; the record it builds feeds the eventual REMS discussion).
• ~Q4 2026 (est., company-guided) — completion of all modules of the rolling NDA for COMP360 in TRD. The only company-controlled milestone left this year.
• ~2026-11-04 (est.) — Q3 2026 results: first cash-burn update after the shelf filing and the checkpoint on whether Q4 NDA completion still holds.
• ~H1 2027 (est., company-guided) — US commercial launch, conditional on FDA approval and DEA rescheduling.

What Would Change Our Mind

The structure that matters is the post-readout consolidation the stock has held since early August. Losing it in full — a weekly close below $11.50 — would give back more than half the July COMP006 leg and put the regulatory story back to where it traded before the data. Three non-price conditions carry equal weight. First, a priced follow-on or ATM supplement off the 2026-08-05 mixed shelf at a discount to the tape, which converts registered capacity into dilution against the 135.7M share base. Second, any language change away from "all modules in Q4" at the Q3 print, which would push the H1 2027 launch guide and reset every model built on it. Third, the 2026-09-14 hearing coming and going with testimony pointing toward heavy credentialing and monitoring requirements, which would move the argument from approval odds to cost of delivery. A refuse-to-file letter or clinical hold disclosed by 8-K would end the leg outright regardless of price.

Correlation Notes

• Policy beta dominates: the 2026-09-14 hearing, EO 14401 and any DEA scheduling signal move the whole psychedelic complex — ATAI, MindMed, Enveric — not CMPS alone. The 2026-04-24 FDA acceleration headlines moved several of these names on the same session.
• Pre-revenue clinical-stage with no product sales makes this a duration asset, correlated with small-cap biotech risk appetite (XBI-type flow) and inversely with the long end.
• Idiosyncratic decoupling risk runs through the warrant liability: GAAP results move opposite the share price by construction, so a headline-driven screen can read the print backwards.
• Low-float ADS structure with a history of 15–25% single-session moves on individual headlines in both directions; liquidity thins fast in either tail.